MGC Pharma has been granted a permit by the Australian Office of Drug Control to test the efficacy of its cannabis products in fighting cancer.
The Cannabis Research Cultivation Permit means the company can proceed with botanical research projects in collaboration with RMIT University in a bid to identify new cannabinoids and treatments for a range of medical conditions.
Strains will be screened for anticancer activity, initially melanoma and prostate cancers.
It follows the granting of a Cannabis Research Licence in 2019.
MGC Pharma co-founder and managing director Roby Zomer said: “The grant of a
cannabis research cultivation permit is an important step forward as we
continue to broaden the potential application of our phytocannabinoid-derived medicinal products.
“Importantly, it also allows us to collaborate with other establishments to not
only improve existing genetics, but create new genetics for the Australian market.”
The news comes a week after the company was granted an import licence by the Australian Office of Drug Control to import medicinal cannabis direct from its European production facility.
